Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908413 | 0.81 | DDR1 (0.46) | EPHX2PPARG | |
| SCHEMBL2906483 | 0.78 | LMNA (0.46) | EPHX2LMNAHDAC8MAPK1NLRP1 | |
| SCHEMBL2901573 | 0.76 | EPHX2 (0.51) | EPHX2PPARG | |
| SCHEMBL3032631 | 0.76 | EPHX2 (0.54) | EPHX2 | |
| SCHEMBL2904023 | 0.74 | EPHX2 (0.43) | EPHX2NR1H4 | |
| SCHEMBL2908515 | 0.73 | ADORA2A (0.45) | KDM4EHDAC1 | |
| SCHEMBL2908865 | 0.72 | SCN9A (0.50) | EPHX2LMNAHDAC8MAPK1NLRP1 | |
| SCHEMBL3471137 | 0.71 | LMNA (0.46) | EPHX2LMNAHDAC8MAPK1NLRP1 | |
| SCHEMBL3034301 | 0.70 | EPHX2 (0.53) | EPHX2LMNAHDAC8MAPK1NLRP1 | |
| SCHEMBL2908742 | 0.69 | EPHX2 (0.44) | EPHX2LMNAHDAC8MAPK1NLRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | claimed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, FAH | EPHX2 5/4885NR1H4 27/4885LMNA 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.